Cipla's associate company Avenue Therapeutics submits NDS for IV Tramadol

Avenue Therapeutics (an associate company of Cipla), a company focused on the development of intravenous (IV) tramadol for the U.S. market, on 11 December 2019 announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

Powered by Capital Market - Live News